leisure time -WSS

leisure time

author：knowledge 2025-09-14 18:26:56 - browse：3848

Garry Tan, CEO of Y Combinator Seb Daly/Web Summi

WASHINGTON — In San Francisco, Y Combinator’s firebrand chief executive Garry Tan is one of the startup economy’s most recognizable figures. Well before he became the leader of the coveted startup accelerator that bred global brands like Airbnb, Stripe and OpenAI, Tan was a self-made founder who sold his own company to Twitter.

But here in the nation’s political capital, Tan is far less known. He’s hoping to grow his influence here, offering up his vast network of founders as a source of expertise for regulators struggling to wrap their heads around new technologies like artificial intelligence and how best to rein it in.

“We’re happy to be a phone-a-friend for people who are trying to understand tech,” he told the Economic Club of Washington recently when asked how he’d measure success during Y Combinator’s first-ever policy-focused visit. “‘Little tech’ represents competition, and consumer choice,” he said later at a separate event in a dimly lit Senate room filled with a few dozen Congressional staffers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Novo Nordisk testing Wegovy against alcohol

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

STAT reporters are Pulitzer Prize finalists for investigative reporting

Abbott's new heart device gets FDA advisory panel nod

STAT series 'Denied by AI' wins major journalism prizes

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

AMAs digital advisors table RPM coding reform proposal, again

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Cancer drug shortages should be causing more outrage

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

In Memoriam: Notable people who died in 2023

Report cites 'urgent' need to recruit more diverse clinical trial participants

focus

Long Covid research funding gets a major boost from NIH

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Supreme Court to hear if Covid misinformation is protected speech

What a koala virus tells us about the human genome

Boston hospital trains restaurant workers on naloxone for overdoses

Artificial intelligence use in health care faces greater scrutiny in 2024

focus

leisure time

hotspot

focus